ArticleNeuroradiology2008
Prognostic value of choline and creatine in WHO grade II gliomas.
Article in Neuroradiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis.European radiology · 2016Pooled it
- The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2015Guideline
- Predictions and cross-center validation of IDH status and 1p/19q status in adult diffuse glioma with non-invasive magnetic resonance spectroscopy.Magnetic resonance letters · 2027Article
- Metabolite ratiomics: Rapid diagnosis and classification of gliomas for intraoperative application during brain surgery.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Magnetic Resonance Spectroscopy of Cystathionine and 2-Hydroxyglutarate in Brain Tumors.NMR in biomedicine · 2026Article
- Insights Into CEST Contrast at 2 ppm in Enhancing and Nonenhancing Lesions From Glioma Patients Scanned at 7 T.NMR in biomedicine · 2025Article
- Brain temperature mapping based on chemical exchange saturation transfer signal at 2 ppm.Quantitative imaging in medicine and surgery · 2025Article
- Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate and Glycine in Adult Subjects With Brainstem Gliomas.NMR in biomedicine · 2025Article
- Article
- White Matter Metabolite Ratios Predict Cognitive Outcome in Pediatric Traumatic Brain Injury.Metabolites · 2023Article
- MRS as an Aid to Diagnose Malignant Transformation in Low-Grade Gliomas with Increasing Contrast Enhancement.AJNR. American journal of neuroradiology · 2020Article
- The Role of Imaging Biomarkers Derived From Advanced Imaging and Radiomics in the Management of Brain Tumors.Frontiers in oncology · 2020Article
- Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.Technology in cancer research & treatment · 2019Article
- Assessment of Overall Survival in Glioma Patients as Predicted by Metabolomic Criteria.Frontiers in oncology · 2019Article
- [Magnetic resonance spectroscopy of brain tumors].Der Radiologe · 2017Article
- Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.Journal of neuro-oncology · 2017Article
- Interrogating Metabolism in Brain Cancer.Magnetic resonance imaging clinics of North America · 2016Review
- Magnetic Resonance (MR) Metabolic Imaging in Glioma.Brain pathology (Zurich, Switzerland) · 2015Review
- Whole Brain ¹H-Spectroscopy: A Developing Technique for Advanced Analysis of Cerebral Metabolism.Clinical neuroradiology · 2015Review
- Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma.Seminars in radiation oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe purpose of this study was to evaluate whether proton magnetic resonance spectroscopy ((1)H-MRS) predicts survival time, tumor progression, and malignant transformation in patients with WHO grade II gliomas. MATERIALS AND
methods(1)H-MRS and MR imaging (MRI) were performed before surgery in 45 patients with histologically proven WHO grade II gliomas. Metabolite concentrations of choline-containing compounds (Cho) and creatine/phosphocreatine (tCr) were normalized to contralateral brain tissue. Spectroscopic data as well as the extent of tumor resection, contrast enhancement, size and histopatholocical type of the tumor, age, sex, and first neurological symptoms of the patients were analyzed for survival, tumor progression, and malignant transformation for a follow-up period of 1 to 5 years.
resultsThe normalized tCr of WHO grade II gliomas was a significant predictor for tumor progression (p = 0.011) and for malignant tumor transformation (p = 0.016). Further, contrast enhancement of the tumor (p = 0.014) at the time of diagnosis was significant for malignant tumor transformation and extent of tumor resection for the tumor progression (p = 0.007). All other parameters failed to predict any of the three endpoints.
conclusionNormalized values of tCr in WHO grade II gliomas may have prognostic implications for this group of gliomas. As a rule of the thumb, low-grade gliomas with decreased tCr (relative tCr values below 1.0) may show longer progression-free times and later malignant transformation than low-grade gliomas with regular or increased tCr values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.